Product Information
GNP DUAL ACTION PAIN 250-125 MG is a generic product labeled by AmerisourceBergen, priced at $0.1071 per EA under NDC 46122081861. Its NADAC has been published 54 times since Sep 24, 2025.
FDA first approved this application on Aug 1, 2023.
Strength
250; 125 mg/1; mg/1
Manufacturer
AmerisourceBergenNDC
46122081861
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA216999FDA Approved
8/1/2023
On Market Since
5/15/2025
Pharmacological Classes
Price Statistics
The NADAC for GNP DUAL ACTION PAIN 250-125 MG has been published 54 times since Sep 24, 2025, and over the history we have for it it has risen 20.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1071 per EA |
|---|---|
| All-time high | $0.1071 (Sep 30, 2026) |
| All-time low | $0.0839 (Apr 22, 2026) |
| 52-week high | $0.1071 |
| 52-week low | $0.0839 |
| Median price | $0.0905 |
| Average price | $0.0927 |
| Largest weekly change | +11.2% (Jul 22, 2026) |
| Weeks tracked | 54 |
| Tracking since | Sep 24, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 21% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AmerisourceBergen manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen and Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GNP DUAL ACTION PAIN 250-125 MG?
The current National Average Drug Acquisition Cost (NADAC) for GNP DUAL ACTION PAIN 250-125 MG, manufactured by AmerisourceBergen, is $0.1071 per EA (NDC 46122081861), effective Sep 30, 2026.
How has the price of GNP DUAL ACTION PAIN 250-125 MG changed over time?
Over the history we have for it, the NADAC for GNP DUAL ACTION PAIN 250-125 MG has risen 20.1%. It has been tracked across 54 weekly CMS publications since Sep 24, 2025.
What are the highest and lowest recorded NADAC prices for GNP DUAL ACTION PAIN 250-125 MG?
Since Sep 24, 2025, the NADAC for GNP DUAL ACTION PAIN 250-125 MG has ranged from a low of $0.0839 (Apr 22, 2026) to a high of $0.1071 (Sep 30, 2026), with a median of $0.0905 per EA.
Are there cheaper alternatives to GNP DUAL ACTION PAIN 250-125 MG?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ACETAMINOPHEN-IBUPROFEN 250-125 MG CAPLET, is $0.0844 per EA — about 21% below GNP DUAL ACTION PAIN 250-125 MG.
Who manufactures GNP DUAL ACTION PAIN 250-125 MG?
GNP DUAL ACTION PAIN 250-125 MG (NDC 46122081861) is labeled by AmerisourceBergen, and CMS classifies it as a generic product.